Seminars in Oncology
Volume 29, Issue 3 , Pages 246-257 , June 2002

P53 gene mutations: Case study of a clinical marker for solid tumors

References 

  1. Ravdin PM, Green S, Dorr TM, et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10:1284–1291
  2. McGuire WL, Clark GM. Role of progesterone receptors in breast cancer. Semin Oncol. 1985;12:12–16
  3. Muss HB, Thor AD, Berry DA, et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266
  4. Seeger RC, Brodeur GM, Sather H, et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–1116
  5. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331
  6. Vousden KH. p53: Death star. Cell. 2000;103:691–694
  7. Ladanyi M, Lewis R, Jhanwar SC, et al.  MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol. 1995;175:211–217
  8. James MC, Peters G. Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors. Prog Cell Cycle Res. 2000;4:71–81
  9. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42–55
  10. Greenblatt MS, Bennett WP, Hollstein M, et al.  Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855–4878
  11. Schmale H, Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene. 1997;15:1363–1367
  12. Osada M, Ohba M, Kawahara C, et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med. 1998;4:839–843
  13. Kaelin WG. Another p53 Doppelganger?. Science. 1998;281:57–58
  14. Donehower LA, Harvey M, Slagle BL, et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221
  15. Baker S, Preisinger AC, Jessup MC, et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717–7722
  16. Hall PA, Lane DP. p53 in tumour pathology: Can we trust immunohistochemistry?—Revisited!. J Pathol. 1994;172:1–4
  17. Gannon JV, Greaves R, Iggo R, et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990;9:1595–1602
  18. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell. 1994;78:539–542
  19. Weinstein JN, Myers TG, O'Connor PM, et al.  An information-intensive approach to the molecular pharmacology of cancer. Science. 1997;275:343–349
  20. Lowe SW, Ruley HE, Jacks T, et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967
  21. Lowe SW, Bodis S, McClatchey A, et al.  p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–810
  22. Chin KV, Ueda K, Pastan I, et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459–462
  23. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996;56:892–898
  24. Malkin D, Li FP, Strong LC, et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science. 1990;250:1233–1238
  25. Pricolo VE, Finkelstein SD, Hansen K, et al.  Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg. 1997;132:371–374
  26. Augenlicht LH, Wadler S, Arango D. Clinical response to fluorouracil and p53. N Engl J Med. 2001;345:1065; (letter)
  27. Watanabe T, Wu TT, Catalano PJ, et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–1206
  28. Elsaleh H, Powell B, McCaul K, et al.  P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001;7:1343–1349
  29. Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation. Urology. 1997;157:1655–1659
  30. Lacombe L, Dalbagni G, Zhang ZF, et al.  Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome. J Clin Oncol. 1996;14:2646–2652
  31. Ick K, Schultz M, Stout P, et al.  Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment. Urology. 1997;49:541–547
  32. Casetta G, Gontero P, Russo R, et al.  p53 expression compared with other prognostic factors in Oms grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol. 1997;32:229–236
  33. Sarkis AS, Zhang ZF, Cordon-Cardo C, et al.  p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol. 1993;3:355–360
  34. Esrig D, Elmajian D, Groshen S, et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264
  35. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst. 1993;85:53–59
  36. Sarkis AS, Bajorin DF, Reuter VE, et al.  Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13:1384–1390
  37. Keegan PE, Lunec J, Neal DE. p53 and p53-regulated genes in bladder cancer. Br J Urol. 1998;82:710–720
  38. Cote RJ, Esrig D, Groshen S, et al.  p53 and treatment of bladder cancer. Nature. 1997;385:123–125
  39. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998;52:79–98
  40. Allred DC, Clark G, Fuqua S, et al.  Overexpression of p53 in node-positive breast cancer. Breast Cancer Res Treat. 1993;27:131
  41. Allred DC, Clark GM, Elledge R, et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200–206
  42. Elledge R, Fuqua S, Clark GM, et al.  Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993;26:225–235
  43. Gasparini G, Weidner N, Bevilacqua P, et al.  Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994;12:454–466
  44. Sjogren S, Inganas M, Norberg T, et al.  The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996;88:173–182
  45. Thor A, Moore D, Edgerton S, et al.  Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845–855
  46. Ioakim-Liossi A, Ioakim-Liossi A, Karakitsos P, et al.  p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. Cytopathology. 2001;12:197–202
  47. Fitzgibbons PL, Page DL, Weaver D, et al.  Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966–978
  48. Beenken SW, Grizzle WE, Crowe DR, et al.  Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53. Ann Surg. 2001;233:630–638
  49. Rosen PP, Lesser ML, Arroyo CD, et al.  p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995;13:821–830
  50. Greenblatt MS, Chappuis PO, Bond JP, et al.  TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res. 2001;61:4092–4097
  51. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53, and BCL-2. Ann Oncol. 2000;11:647–663
  52. Aas T, Borresen A, Geisler S, et al.  Specific p53 mutations are associated with de novo reistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814
  53. Bergh J, Norberg T, Sjogren S, et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029–1034
  54. Faille A, De Cremoux P, Extra J, et al.  p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994;69:1145–1150
  55. Stal O, Askmalm M, Wingren S, et al.  p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol. 1995;34:767–770
  56. Linn SC, Pinedo HM, van Ark-Otte J, et al.  Expression of drug resistance in breast cancer, in relation to chemotherapy. Int J Cancer. 1997;71:787–795
  57. Rozan S, Vincent-Salomon A, Zafrani B, et al.  No significant predictive value of c-erb-B2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer. 1998;79:27–33
  58. Elledge RM, Gray R, Mansour E, et al.  Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J Natl Cancer Inst. 1995;87:1254–1256
  59. Komiya T, Hirashima T, Kawase I. Clinical significance of p53 in non-small cell lung cancer (review). Oncol Rep. 1999;6:19–28
  60. Lucchi M, Fontanini G, Mussi A, et al.  Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg. 1997;12:535–541
  61. Pastorino U, Andreola S, Tagliabue E, et al.  Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol. 1997;15:2858–2865
  62. Harpole D, Herndon JN, Wolfe WG, et al.  A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995;55:51–56
  63. Berner A, Geitvik G, Karlsen F, et al.  TP53 mutations in prostatic cancer. Analysis of pre- and post- treatment archival formalin-fixed tumour tissue. J Pathol. 1995;176:299–308
  64. Wertz IE, Deitch AD, Gumerlock PH, et al.  Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol. 1996;27:573–580
  65. Navone NM, Troncoso P, Pisters LL, et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993;85:1657–1669
  66. Yang G, Stapleton AMF, Wheeler TM, et al.  Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996;2:399–401
  67. Bauer JJ, Sesterhenn IA, Mostofi KF, et al.  p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res. 1995;1:1295–1300
  68. Grignon DJ, Caplan R, Sarkar FH, et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst. 1997;89:158–165
  69. Visakorpi T, Kallioniemi OP, Heikkinen A, et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst. 1992;84:883–887
  70. Thomas DJ, Robinson M, King P, et al.  p53 expression and clinical outcome in prostate cancer. Br J Urol. 1993;72:778–781
  71. Vesalainen SL, Lipponen PK, Talja MT, et al.  Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int J Cancer. 1994;58:303–308
  72. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 1995;26:106–109
  73. Bauer JJ, Sesterhenn IA, Mostofi FK, et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156:1511–1516
  74. Moul JW, Bettencourt MC, Sesterhenn IA, et al.  Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery. 1996;120:159–167
  75. Matsushima H, Kitamura T, Goto T, et al.  Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol. 1997;158:2278–2283
  76. Theodorescu D, Broder SR, Boyd JC, et al.  p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 1997;158:131–137
  77. Stapleton AM, Zbell P, Kattan MW, et al.  Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998;82:168–175
  78. Uzoaru I, Rubenstein M, Mirochnik Y, et al.  An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol. 1998;67:33–37
  79. Masuda M, Takano Y, Iki M, et al.  Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: A retrospective immunohistochemical analysis. Pathol Int. 1998;48:41–46
  80. McDonnell TJ, Navone NM, Troncoso P, et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997;157:569–574
  81. Cheng L, Leibovich BC, Bergstralh EJ, et al.  p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?. Cancer. 1999;85:2455–2459
  82. Temam S, Flahault A, Perie S, et al.  p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2000;18:385–394
  83. Cabelguenne A, Blons H, de Waziers I, et al.  p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol. 2000;18:1465–1473
  84. Brennan JA, Sidransky D. Molecular staging of head and neck squamous carcinoma. Cancer Metast Rev. 1996;15:3–10
  85. Bian YS, Osterheld MC, Bosman FT, et al.  p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol. 2001;14:397–403
  86. Khan S, Do KA, Kuhnert P, et al.  Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: An endoscopic study. Pathology. 1998;30:136–140
  87. Boyle JO, Hakim J, Koch W, et al.  The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993;53:4477–4480
  88. Brennan JA, Boyle JO, Koch WM, et al.  Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:712–717
  89. Lee JJ, Hong WK, Hittelman WN, et al.  Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res. 2000;6:1702–1710
  90. Hittelman WN, Shin DM, Mao L, et al.  Pretreatment biomarkers predict response of advanced head and neck premalignant lesions to biochemoprevention. Proc Am Soc Clin Oncol. 2000;19:1636; (abstr)
  91. Sidransky D, Von Eschenbach A, Tsai YC, et al.  Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252:706–709
  92. Lane DP. Cancer: p53, guardian of the genome. Nature. 1992;358:15–16
  93. Duddy PM, Hanby AM, Barnes DM, et al.  Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. J Mol Diagn. 2000;2:139–144

☆ Address reprint requests to Edward P. Gelmann, MD, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, 3800 Reservoir Rd NW, Washington, DC 20007-2197. Email gelmanne@georgetown.edu.

PII: S0093-7754(02)50180-9

doi: 10.1053/sonc.2002.32900

Seminars in Oncology
Volume 29, Issue 3 , Pages 246-257 , June 2002

Article Tools

* Image Usage & Resolution